PEX7

Across TCGA pan-cancer cohorts, PEX7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PEX7 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PEX7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PEX7 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PEX7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.312	0.694	.006	22	view →
LUAD	OS	Median	All	0.905	1.000	.005	14	view →
LSCC	OS	Tertile	All	0.897	0.650	.022	9	view →
HNSC	OS	Quartile	III,IV	0.450	0.781	.012	6	view →
UCEC	DFS	Tertile	All	1.000	0.917	.048	2	view →
CCRCC	DFS	Tertile	II,III,IV	0.440	0.685	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PEX7–PDAC (OS)

Open the PDAC breakdown →